The growing role of precision and personalized medicine for cancer treatment.

TECHNOLOGY Pub Date : 2018-09-01 Epub Date: 2019-01-11 DOI:10.1142/S2339547818300020
Paulina Krzyszczyk, Alison Acevedo, Erika J Davidoff, Lauren M Timmins, Ileana Marrero-Berrios, Misaal Patel, Corina White, Christopher Lowe, Joseph J Sherba, Clara Hartmanshenn, Kate M O'Neill, Max L Balter, Zachary R Fritz, Ioannis P Androulakis, Rene S Schloss, Martin L Yarmush
{"title":"The growing role of precision and personalized medicine for cancer treatment.","authors":"Paulina Krzyszczyk, Alison Acevedo, Erika J Davidoff, Lauren M Timmins, Ileana Marrero-Berrios, Misaal Patel, Corina White, Christopher Lowe, Joseph J Sherba, Clara Hartmanshenn, Kate M O'Neill, Max L Balter, Zachary R Fritz, Ioannis P Androulakis, Rene S Schloss, Martin L Yarmush","doi":"10.1142/S2339547818300020","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer is a devastating disease that takes the lives of hundreds of thousands of people every year. Due to disease heterogeneity, standard treatments, such as chemotherapy or radiation, are effective in only a subset of the patient population. Tumors can have different underlying genetic causes and may express different proteins in one patient versus another. This inherent variability of cancer lends itself to the growing field of precision and personalized medicine (PPM). There are many ongoing efforts to acquire PPM data in order to characterize molecular differences between tumors. Some PPM products are already available to link these differences to an effective drug. It is clear that PPM cancer treatments can result in immense patient benefits, and companies and regulatory agencies have begun to recognize this. However, broader changes to the healthcare and insurance systems must be addressed if PPM is to become part of standard cancer care.</p>","PeriodicalId":22332,"journal":{"name":"TECHNOLOGY","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352312/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TECHNOLOGY","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/S2339547818300020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/11 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer is a devastating disease that takes the lives of hundreds of thousands of people every year. Due to disease heterogeneity, standard treatments, such as chemotherapy or radiation, are effective in only a subset of the patient population. Tumors can have different underlying genetic causes and may express different proteins in one patient versus another. This inherent variability of cancer lends itself to the growing field of precision and personalized medicine (PPM). There are many ongoing efforts to acquire PPM data in order to characterize molecular differences between tumors. Some PPM products are already available to link these differences to an effective drug. It is clear that PPM cancer treatments can result in immense patient benefits, and companies and regulatory agencies have begun to recognize this. However, broader changes to the healthcare and insurance systems must be addressed if PPM is to become part of standard cancer care.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
精准和个性化药物在癌症治疗中的作用越来越大。
癌症是一种毁灭性疾病,每年夺走数十万人的生命。由于疾病的异质性,标准治疗,如化疗或放疗,仅对患者群体的一部分有效。肿瘤可能有不同的潜在遗传原因,并且可能在一名患者和另一名患者中表达不同的蛋白质。癌症的这种固有变异性有助于精确和个性化医疗(PPM)领域的发展。为了表征肿瘤之间的分子差异,正在进行许多获取PPM数据的努力。一些PPM产品已经可以将这些差异与有效药物联系起来。很明显,PPM癌症治疗可以给患者带来巨大的好处,公司和监管机构已经开始认识到这一点。然而,如果PPM要成为标准癌症护理的一部分,就必须解决医疗保健和保险系统的更广泛变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
TECHNOLOGY
TECHNOLOGY ENGINEERING, MULTIDISCIPLINARY-
自引率
0.00%
发文量
0
期刊最新文献
Twenty-four hour ex-vivo normothermic machine perfusion in rat livers. First-in-human evaluation of a hand-held automated venipuncture device for rapid venous blood draws. A protein interaction free energy model based on amino acid residue contributions: Assessment of point mutation stability of T4 lysozyme. The growing role of precision and personalized medicine for cancer treatment. Automated end-to-end blood testing at the point-of-care: Integration of robotic phlebotomy with downstream sample processing.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1